Sionna Therapeutics, Inc. (SION) AI Stock Analysis

• Market Cap: $1.66B
• Dividend Yield: N/A
• Average Volume (3M): 299.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.46
• Shares Outstanding: 44,998,074
• 10 Day Avg. Volume: 346,705
• 30 Day Avg. Volume: 299,130
• PEG Ratio: -0.64
• Price to Book (P/B): 5.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.66
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.04K
• Enterprise Value/Ebitda: -21.43
• 1Y Price Target: $51.17
• Price Target Upside: 39.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -2.33
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $39.00 ▲(6.09% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held down by pre-revenue operations with widening losses and significant, persistent cash burn. A strengthened 2025 balance sheet with low debt provides some stability, but technicals remain weak with the stock below key short- and mid-term moving averages and negative MACD. Valuation support is limited because the negative P/E is driven by losses and no dividend yield is available.

Positive Factors

Low Leverage

Very low absolute debt and a debt-to-equity around 0.03 materially reduce solvency risk and preserve strategic optionality. With limited leverage the company can sustain multi-quarter R&D spend, pursue collaborations, or time financing to favorable windows without immediate distress.

Negative Factors

Pre-Revenue Operations

Sionna remains pre-revenue while operating losses have widened (EBIT to -$88.98M in 2025). Without product revenues, the firm depends on capital markets or partners to fund R&D and operations, making execution on clinical programs and timing of first revenue the key long-term risks.

Sionna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator....

How the Company Makes Money

null...

Sionna Therapeutics, Inc. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	-647.00K	-668.00K	0.00	0.00
EBITDA	-88.33M	-69.89M	-49.75M	-41.25M
Net Income	-75.27M	-61.69M	-47.26M	-40.24M
Balance Sheet
Total Assets	325.95M	185.75M	51.95M	87.37M
Cash, Cash Equivalents and Short-Term Investments	235.88M	147.54M	38.52M	82.61M
Total Debt	8.68M	9.75M	10.48M	0.00
Total Liabilities	19.12M	349.46M	166.83M	157.29M
Stockholders Equity	306.83M	-163.71M	-114.88M	-69.92M
Cash Flow
Free Cash Flow	-66.67M	-52.81M	-44.81M	-37.94M
Operating Cash Flow	-66.30M	-52.79M	-43.70M	-36.07M
Investing Cash Flow	-118.75M	-126.91M	27.35M	-29.26M
Financing Cash Flow	205.71M	178.97M	31.00K	110.86M

Sionna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	63 Neutral	$1.52B	-1.91	-49.31%	―	-78.55%	7.74%
STOK	58 Neutral	$2.06B	-273.00	-2.05%	―	1128.17%	―
TNGX	55 Neutral	$2.86B	-6.64	-50.30%	―	53.28%	21.77%
AMLX	52 Neutral	$1.87B	-7.89	-57.52%	―	-100.34%	52.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMTX	51 Neutral	$1.41B	-5.79	-39.69%	―	-27.61%	-69.49%
SION	45 Neutral	$1.66B	-20.11	-22.87%	―	―	―